On November 27, 2019 Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, reported with Eli Lilly and Company ("Lilly") that the innovative PD-1 inhibitor Tyvyt (sintilimab injection), co-developed by both companies, is the only PD-1 inhibitor that has been included in the new Catalogue of National Reimbursement Drug List ("NRDL") according to the latest announcement from the National Healthcare Security Administration ("NHSA") (Press release, Innovent Biologics, NOV 27, 2019, View Source [SID1234551765]). (Details of medical insurance reimbursement and other relevant information shall be subject to the information publicized by the Chinese government.)

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The inclusion of Tyvyt (sintilimab injection) to the NRDL demonstrates that the NHSA has recognized its clinical value, patients benefit and novelty among other factors. This will also allow more patients to be able to afford the new immunotherapy drugs to improve their lives.

Dr. Michael Yu, Founder, Chairman and Chief Executive Officer of Innovent, said: "In recent years, the country’s healthcare system reform has been systematically promoting the ‘Healthy China’ strategy, to improve the health and well-being of ordinary people. We are glad to have such an opportunity and recognition from the government, making sintilimab the only anti-PD-1 monoclonal antibody drug to be included in the NRDL. Innovent’s mission is to develop and commercialize high quality biopharmaceuticals that are affordable to ordinary people. We will continue to work together with all relevant parties to improve drug efficacy, accessibility and affordability, which contributing to making a better and healthier life for ordinary people."

Mr. Julio Gay-Ger, President and General Manager of Eli Lilly China, said: "Tyvyt (sintilimab injection) is the first achievement of the strategic cooperation between Eli Lilly and Innovent, and its launch in the 1st half of this year has brought a new choice of immunotherapy for many patients. The negotiation to enter the NRDL is to improve the accessibility and further reduce the economic burden of patients. In the future, we will continue to deepen our cooperation with Innovent, and work together with all stakeholders to benefit Chinese patients through innovative drugs, healthcare services, flexible payment schemes and other innovative approaches."

Mr. Min Liu, Chief Commercial Officer and General Manager of Shanghai Branch of Innovent, said: "We believe that the inclusion of Tyvyt (sintilimab injection) in the NRDL will further help more cancer patients alleviate their economic burden and receive long-term and most advanced treatment. Next, we will actively respond to the requirements of government, work together closely to implement the medical insurance policies, and accelerate the accessibility of sintilimab in the hospital channel. We will also continue to explore innovative payment schemes with relevant parties, and strive to enable more patients to benefit from the scientific progress."

Tyvyt (Recombinant anti-human PD-1 Monoclonal Antibody, international trademark: Tyvyt, generic name: sintilimab injection) is an innovative PD-1 inhibitor jointly developed by Lilly and Innovent. It was officially approved by National Medical Products Administration ("NMPA") on 24 December 2018 and used for the treatment of relapsed or refractory classic Hodgkin’s lymphoma ("r/r cHL") after at least second-line system chemotherapy.

About Tyvyt (Sintilimab Injection)

Tyvyt (sintilimab injection), an innovative drug jointly developed in China by Innovent and Lilly, has been granted marketing approval by the NMPA for r/r cHL, and included in the 2019 Guidelines of Chinese Society of Clinical Oncology ("CSCO") for Lymphoid Malignancies. Tyvyt (sintilimab injection) is the only PD-1 inhibitor that has been included in the NRDL in November 2019.

Tyvyt (sintilimab injection) is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-1 Ligand-1 (PD-L1) pathway and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies for sintilimab injection to evaluate its safety and efficacy in a wide variety of cancer indications, including eight registration or pivotal clinical trials. Innovent is also conducting clinical studies of sintilimab injection in the United States.

On November 27, 2019 Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, reported the completion of a US$ 43 million (RMB 304 million) Series B financing (Press release, Clover Biopharmaceuticals, NOV 27, 2019, View Source [SID1234551764]). This financing round brings Clover’s total capital raised since 2016 to over US$ 100 million (over RMB 750 million).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Series B round was led by Delos Capital and Lapam Capital, with participation from Betta Capital, Sichuan Health Care Industry Fund, Beijing Zhongguancun VC and Jinlong Group. Concurrent with the financing, Mr. Tim Xiao, CFA, FRM, Principal of Delos Capital and Mr. Guangyu Xu, Partner of Lapam Capital, will join Clover’s board of directors. BFC Group served as exclusive financial advisor to Clover for the financing round.

The proceeds will support the continued clinical development of Clover’s biological candidates, operations of its new commercial-scale cGMP biomanufacturing facility, and expansion of its preclinical R&D pipeline utilizing its innovative and proprietary Trimer-Tag© technology platform. SCB-313, a novel TRAIL-Trimer fusion protein targeting intracavitary malignancies (malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis), has initiated multiple Phase I clinical trials globally in both Australia and China. SCB-808, a proposed biosimilar of Enbrel (etanercept) being developed in the prefilled syringe formulation, is expected to enter Phase III clinical testing in 2019. Clover’s state-of-the-art 35,000m2 cGMP biomanufacturing facility, with initial 2 x 2,000 L bioreactor capacity, has completed construction and will support Clover’s clinical trials as well as future commercial production.

"As a research-based, science-driven biotechnology company, our mission has always been to bring our innovative biologic therapies to the world by leveraging our proprietary Trimer-Tag© drug development platform with global IP position, state-of-the art cGMP biomanufacturing capabilities, and passionate team of scientists and highly-experienced industry professionals," said Dr. Peng Liang, co-founder, Chairman and President of Clover. "We look forward to using the proceeds from this financing round to further accelerate our drug development and move closer to our goal of becoming the first truly-innovative global biologics R&D powerhouse founded in China."

"We are pleased to complete this financing round, as it will allow us to advance our lead biologic candidates into late-stage clinical development, expand our internal R&D capabilities and continue to build a world-class team," said Joshua Liang, Chief Strategy Officer and Board Director of Clover. "As one of the few global biotechnology companies based in China with both a truly innovative drug development platform and in-house cGMP biomanufacturing capabilities, we are pleased that renowned investors have recognized the potential of our company."

"We are proud to invest in Clover, which has made great strides in advancing its proprietary platform technology from concept to human clinical proof-of-concept and is targeting diseases of high unmet medical needs globally. We look forward to supporting the company in their development and also helping to create additional value from global collaborations," said Tim Xiao, Principal of Delos Capital.

"We are very impressed with Clover’s fully-integrated biologics development capabilities as well as its scientific team and technology platforms. We look forward to helping Clover bring their innovative and impactful medicines to market quickly and efficiently for the benefit of patients," said Guangyu Xu, Partner of Lapam Capital.

On November 27, 2019 MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) reported its results for the three and nine-months ended September 30, 2019, which are also available on SEDAR (www.sedar.com) (Press release, MedX Health, NOV 27, 2019, View Source [SID1234551762]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company reported revenue of $234,977 for the three months ended September 30, 2019, compared with revenue of $180,404 for the three months ended September 30, 2018. Revenues from the Company’s therapeutic laser line of $177,437 were 41% higher than in the prior year. SIAscopy revenues of $57,541 also showed improvement over the 2018 three-month period. The Company reported a loss for the three months ended September 30, 2019 of $577,648 or $0.00 per share compared with a loss of $919,935, or $0.01 per share for the three months ended September 30, 2018.

The Company reported revenue of $678,886 for the nine months ended September 30, 2019, compared with revenue of $812,233 for the nine months ended September 30, 2018. Revenues from the Company’s therapeutic laser line of $574,070 were up 13% for the nine-month period, while SIAscopy revenues were lower than the prior year. The Company reported a loss for the nine months ended September 30, 2019 of $2,086,892 or $0.01 per share compared with a loss of $3,171,333, or $0.02 per share for the nine months ended September 30, 2018.

"We experienced an increase in our SIAscopy product sales in Q3, a positive sign, with our Brazilian distribution partners participating in industry conferences and building the awareness level and interest in our DermSecure telemedicine platform by local dermatologists, as we get closer to regulatory approval in that country," noted Scott Spearn, CEO of MedX. "We expect to see further interest and increased revenue from the platform as we move into 2020, as the market realizes the benefits of our technology and how we can be a leader in shortening wait times, saving lives and lowering costs to the health care system. In addition, sales from our therapeutic laser products were solid again this quarter, up 41% over last year in Q3, and now 13% higher on a year-to-date basis."

On November 27, 2019 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, reported participation at the following upcoming conferences (Press release, Rocket Pharmaceuticals, NOV 27, 2019, View Source [SID1234551761]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evercore ISI 2nd Annual HealthCONx Conference
Gaurav Shah, M.D., President and CEO, is scheduled to present on Tuesday, December 3, 2019, at 11:20 a.m. Eastern Time.
Piper Jaffray’s 31st Annual Healthcare Conference
Gaurav Shah, M.D., President and CEO, is scheduled to present on Thursday, December 5, 2019, at 1:00 p.m. Eastern Time.
A live audio webcast of the presentations will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentations will be archived on the Rocket website following the conferences.

On November 27, 2019 NantKwest, Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, reported that on Monday, December 2, 2019, it will host a key opinion leader (KOL) meeting in New York City on the current treatment landscapes and unmet medical needs of patients with Merkel cell carcinoma, triple-negative breast cancer, solid tumors and the state-of-the-art treatment in the induction of Immunogenic Cell Death (Press release, NantKwest, NOV 27, 2019, https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-hosting-key-opinion-leader-meeting-novel?field_nir_news_date_value[min]=2019 [SID1234551760]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This event will feature presentations from KOLs George Ansstas, MD, Washington University of Medicine in St. Louis, Chaitali Nangia, MD, Chan Soon-Shiong Institute for Medicine, and Clint Allen, MD, Johns Hopkins Kimmel Cancer Center, as well as Dr. Patrick Soon-Shiong, Chief Executive Officer and Chairman of NantKwest.

NantKwest’s management team will also provide pipeline updates on their haNK and PD-L1.t-haNK programs utilizing the Company’s Activated Natural Killer (aNK) cell platform to target these diseases. This platform harnesses the power of the innate immune system and is uniquely positioned to provide broadly available, off-the-shelf cell therapies capable of being administered in the outpatient setting.

Clint Allen, MD is an Associate Professor of Otolaryngology-Head and Neck Surgery at the Johns Hopkins School of Medicine, Principal Investigator of the Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, NIH. His research focuses on understanding how the immune system responds to squamous cell carcinoma of the head and neck, and how this can be enhanced therapeutically. He leads a large pre-clinical and clinical laboratory program focused on translational pre-clinical studies in syngeneic models of squamous cell carcinoma and the assessment of clinical trial specimens. He is the director of the inpatient Otolaryngology consultation service at the NIH Clinical Center and maintains a surgical practice for the Johns Hopkins School of Medicine based out of Suburban Hospital in Bethesda, MD.

George Ansstas, MD is an Assistant Professor of Medicine, Section of Medical Oncology, Division of Oncology at Washington University School of Medicine. Dr. Ansstas’s clinical expertise includes brain tumors, neuro-oncology, skin cancer, and melanoma. He received his medical degree from University of Tishreen, Latakia, Syria in 2001. Dr. Ansstas completed a fellowship in hematology and oncology at Washington University, St. Louis.

Chaitali Nangia, MD is an Hematologist/Oncologist based in Costa Mesa, California and is affiliated with Hoag Hospital System. She received her medical degree from Lady Hardinge Medical College in New Delhi, India and completed her residency in Internal Medicine at Resurrection Westlake Medical Center in Illinois. She then completed her Fellowship in Hematology/Oncology at the Henry Ford Hospital in Michigan. She worked as an Associate Professor at University of California-Irvine and as an Associate Program Director at University of California-Irvine Hematology/Oncology Fellowship Program prior to her current role. She acted as the principal investigator for several clinical trials and has been an author of several publications.

This event is intended for institutional investors, sell-side analysts, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. Members of the media and the public are invited to participate via the live webcast, which can be accessed through our company website at https://nantkwest.com/nantkwest-key-opinion-leader-event/. The event is expected to start at noon EST on Monday, December 2, 2019.